DIANTHUS THERAPEUTICS, INC.
DNTHLoading price...
Overview
Previous Close65.20
Open79.00
Ask98.47
Bid60.38
Day's Range76.07 - 84.86
52 Week Range13.37 - 84.86
PE Ratio(TTM)--
Market Cap3.43B
Volume4.26M
Avg. Volume794.85k
12 Months Earnings-126.34M
12 Months Revenue3.08M
Profit/Loss
| PARTICULARS | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Operating Revenue | 3.08M | 4.85M | 6.24M | 2.83M | 6.42M | 1.48M |
| Operating Expenses | 143.39M | 134.77M | 108.10M | 51.00M | 36.12M | 14.56M |
| Profit after Tax (Net Income) | -126.34M | -114.75M | -84.97M | -43.55M | -28.48M | -13.11M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: New York, United States
Website: https://dianthustx.com
President, CEO & Director: Mr. Marino Garcia M.B.A.
Employees: 78
About Company:
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company's lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.